CN104114184B - 用于治疗自身免疫性和炎症性疾病的方法和组合物 - Google Patents

用于治疗自身免疫性和炎症性疾病的方法和组合物 Download PDF

Info

Publication number
CN104114184B
CN104114184B CN201280049868.XA CN201280049868A CN104114184B CN 104114184 B CN104114184 B CN 104114184B CN 201280049868 A CN201280049868 A CN 201280049868A CN 104114184 B CN104114184 B CN 104114184B
Authority
CN
China
Prior art keywords
rhob
antibody
seq
inflammatory
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280049868.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104114184A (zh
Inventor
丽莎·劳里-克莱恩托普
劳拉·曼迪科-纳亚克
乔治·C·普伦德加斯特
詹姆斯·杜哈达维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lankenau Institute for Medical Research
Original Assignee
Lankenau Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Institute for Medical Research filed Critical Lankenau Institute for Medical Research
Publication of CN104114184A publication Critical patent/CN104114184A/zh
Application granted granted Critical
Publication of CN104114184B publication Critical patent/CN104114184B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201280049868.XA 2011-08-10 2012-08-09 用于治疗自身免疫性和炎症性疾病的方法和组合物 Expired - Fee Related CN104114184B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522009P 2011-08-10 2011-08-10
US61/522,009 2011-08-10
PCT/US2012/050146 WO2013023059A2 (en) 2011-08-10 2012-08-09 Methods and compositions for the treatment of autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
CN104114184A CN104114184A (zh) 2014-10-22
CN104114184B true CN104114184B (zh) 2017-04-19

Family

ID=47669232

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049868.XA Expired - Fee Related CN104114184B (zh) 2011-08-10 2012-08-09 用于治疗自身免疫性和炎症性疾病的方法和组合物

Country Status (10)

Country Link
US (3) US9879092B2 (https=)
EP (1) EP2741771B1 (https=)
JP (1) JP6253580B2 (https=)
KR (2) KR102101478B1 (https=)
CN (1) CN104114184B (https=)
AU (1) AU2012294342B2 (https=)
CA (1) CA2844668C (https=)
ES (1) ES2813415T3 (https=)
RU (1) RU2639540C2 (https=)
WO (1) WO2013023059A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
AU2012294342B2 (en) * 2011-08-10 2017-07-27 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015157644A1 (en) 2014-04-10 2015-10-15 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CN109789201B (zh) 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
US20200200760A1 (en) * 2017-05-16 2020-06-25 Lankenau Institute Of Medical Research Compositions comprising ligands to rhob protein and the uses thereof
KR102276941B1 (ko) * 2018-07-03 2021-07-14 서울대학교산학협력단 류마티스 관절염 치료용 펩티드 및 그의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962672A (en) * 1998-09-18 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of RhoB expression
US6458783B1 (en) * 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022332A2 (en) * 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU735366B2 (en) * 1997-09-29 2001-07-05 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2462653C (en) 2001-11-07 2016-06-07 Aya Jakobovits Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
WO2005017160A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
WO2006112401A1 (ja) * 2005-04-18 2006-10-26 National University Corporation Hamamatsu University School Of Medicine 癌治療用組成物
US20070213354A1 (en) * 2006-03-08 2007-09-13 Amplimed Corporation Compositions and Methods for the Treatment of Multiple Sclerosis
RU2489166C2 (ru) * 2006-04-09 2013-08-10 Джинентех, Инк. Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
JP5354634B2 (ja) * 2007-01-25 2013-11-27 国立大学法人大阪大学 ヒトａｂｈ８タンパク質、それをコードする遺伝子、およびこれらの治療的又は診断的用途
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
AU2010254136B2 (en) * 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
PE20140570A1 (es) 2011-07-01 2014-04-28 Bayer Ip Gmbh Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
AU2012294342B2 (en) 2011-08-10 2017-07-27 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
WO2015157644A1 (en) * 2014-04-10 2015-10-15 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458783B1 (en) * 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
US5962672A (en) * 1998-09-18 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of RhoB expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A role for rhoB in the delamination of neural crest cells from the dorsal neural tube;Jeh-Ping Liu 等;《Development》;19981231;第125卷;5055-5067 *
Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis;JOHN GREENWOOD 等;《The FASEB Journal》;20030531;第17卷;905-907 *

Also Published As

Publication number Publication date
ES2813415T3 (es) 2021-03-23
KR102101478B1 (ko) 2020-04-16
CN104114184A (zh) 2014-10-22
EP2741771B1 (en) 2020-04-29
JP2014529590A (ja) 2014-11-13
US20180094076A1 (en) 2018-04-05
EP2741771A4 (en) 2015-04-15
CA2844668C (en) 2021-03-09
KR20200042013A (ko) 2020-04-22
RU2639540C2 (ru) 2017-12-21
JP6253580B2 (ja) 2017-12-27
EP2741771A2 (en) 2014-06-18
AU2012294342A1 (en) 2014-03-06
US12545744B2 (en) 2026-02-10
WO2013023059A3 (en) 2013-04-04
US9879092B2 (en) 2018-01-30
KR102221068B1 (ko) 2021-02-25
RU2014106933A (ru) 2015-09-20
CA2844668A1 (en) 2013-02-14
US20140227279A1 (en) 2014-08-14
WO2013023059A2 (en) 2013-02-14
US20210040230A1 (en) 2021-02-11
KR20140067027A (ko) 2014-06-03
AU2012294342B2 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
US12545744B2 (en) Anti-RhoB antibodies for the treatment of autoimmune and inflammatory diseases
JP2022169709A (ja) 関節リウマチの治療
US12247069B2 (en) Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders
US20230242674A1 (en) Compositions comprising antibodies to human ido-2
AU2018350372A1 (en) Method
AU2016298108B2 (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders
JP7132256B2 (ja) 関節リウマチの治療
CA2992145C (en) Methods and compositions for the treatment of immunomodulatory diseases and disorders
CA3150054C (en) Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders
HK40021169A (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
HK40021169B (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170419

Termination date: 20200809